Nurix Therapeutics, Inc.
NASDAQ:NRIX · NASDAQ Global Market
+$0.15 today
Vol 3.23M · Avg 1.74M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$264.5M -36.6% | -$193.6M -34.5% | -$143.9M +20.2% | -$180.4M -53.9% | -$117.2M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $18.9M +14.8% | $16.4M +20.3% | $13.7M +26.3% | $10.8M +77.7% | $6.1M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $38.0M +11.9% | $33.9M +0.8% | $33.7M +19.7% | $28.1M +78.0% | $15.8M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$31.6M -71.7% | -$18.4M -191.5% | $20.1M +205.8% | -$19.0M -308.7% | $9.1M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $0 | $0 | $0 -100.0% | $6.0M +200.0% | -$6.0M | $592.6M | $1.3B | $626.2M |
| Inventory | $0 | $0 | $0 | $0 -100.0% | $6.8M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | -$630.0K -112.1% | $5.2M +222.7% | $1.6M +1798.8% | $85.0K -94.7% | $1.6M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$31.0M -31.2% | -$23.6M -227.6% | $18.5M +173.7% | -$25.1M -472.0% | $6.8M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | -$10.2M +6.7% | -$11.0M -125.5% | -$4.9M -864.9% | $636.0K -65.3% | $1.8M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$249.5M -44.5% | -$172.6M -112.1% | -$81.4M +49.1% | -$159.8M -89.4% | -$84.4M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$14.0M -51.0% | -$9.3M -10.4% | -$8.4M +31.4% | -$12.2M -116.3% | -$5.7M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 +100.0% | -$39.4M -138.4% | $102.6M | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$455.7M +35.6% | -$708.0M -187.4% | -$246.3M -2.9% | -$239.4M +31.3% | -$348.5M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $617.5M +34.4% | $459.5M +42.2% | $323.0M +15.9% | $278.8M +13.4% | $245.9M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $0 | $0 | $0 -100.0% | $39.4M +138.4% | -$102.6M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | $147.9M +157.4% | -$257.7M -477.3% | $68.3M +151.1% | $27.2M +125.1% | -$108.3M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $0 | $0 | $0 | $0 | $0 | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $238.6M -50.1% | $478.5M +14774.0% | $3.2M -83.4% | $19.4M -87.1% | $150.2M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | $0 -100.0% | $7.2M | $0 -100.0% | $97.8M +2525.3% | $3.7M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $238.6M -50.9% | $485.7M +14996.9% | $3.2M -97.3% | $117.2M -23.8% | $153.9M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | -$67.0K | $0 | $0 | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $137.0M +147.5% | $55.4M +662.3% | -$9.8M +36.1% | -$15.4M +60.2% | -$38.7M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$263.5M -44.9% | -$181.9M -102.6% | -$89.8M +47.8% | -$172.1M -91.1% | -$90.0M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Tango Therapeutics, Inc.
NASDAQ:TNGX
$3.54B
Kodiak Sciences Inc.
NASDAQ:KOD
$1.88B
UroGen Pharma Ltd.
NASDAQ:URGN
$1.58B
Septerna, Inc.
NASDAQ:SEPN
$1.58B
Fortrea Holdings Inc.
NASDAQ:FTRE
$1.44B
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$1.13B
Xencor, Inc.
NASDAQ:XNCR
$932.46M
Kura Oncology, Inc.
NASDAQ:KURA
$853.03M
Phathom Pharmaceuticals, Inc.
NASDAQ:PHAT
$852.31M
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
$610.42M
SEC Filings
Recent regulatory filings
No filings found.
Does NRIX generate free cash flow?
Nurix Therapeutics, Inc. (NRIX) generated -$263,467,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does NRIX produce?
Operating cash flow was -$249,465,000.00, before capital expenditures of $14.00M.
Explore More
Continue the stock analysis
Jump to another research area for this company.